A Retrospective Review of Tocilizumab for the Management of Blinatumomab (a Bispecific T Cell Engager)-Induced Cytokine Release Syndrome (CRS)

被引：10
|
作者：
Choudhry, Jessica [1 ]
Parson, Mandy [1 ]
Wright, Jacqueline [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-117353
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5211
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
    Viardot, Andreas
    Goebeler, Marie-Elisabeth
    Hess, Georg
    Neumann, Svenja
    Pfreundschuh, Michael
    Adrian, Nicole
    Zettl, Florian
    Libicher, Martin
    Sayehli, Cyrus
    Stieglmaier, Julia
    Zhang, Alicia
    Nagorsen, Dirk
    Bargou, Ralf C.
    BLOOD, 2016, 127 (11) : 1410 - 1416
  • [42] Apoptotic Cells Dramatically Ameliorate the Efficacy of CAR T-Cell Therapy and Prevents Cytokine Release Syndrome (CRS)
    Mevorach, Dror
    Hoizman, Hila
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S233 - S234
  • [43] Management of chimeric antigen receptor T-cell induced cytokine release syndrome: Current and emerging approaches
    Shin, Yunjung H.
    Tian, Xiaofan
    Park, Jiyeon J.
    Kim, Gee Y.
    Aboujaoude, Emily
    Sturgill, Marc G.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) : 159 - 174
  • [44] Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL
    Bhaskar, Shakthi
    Patel, Vivek
    Porter, David L.
    Schuster, Stephen J.
    Nastoupil, Loretta J.
    Perales, Miguel-Angel
    Tomas, Ana Alarcon
    Bishop, Michael R.
    McGuirk, Joseph P.
    Maziarz, Richard T.
    Chen, Andy
    Bachanova, Veronika
    Riedell, Peter A.
    Oluwole, Olalekan O.
    BLOOD, 2022, 140 : 10971 - 10973
  • [45] Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy
    Daoudlarian, D.
    Segot, A.
    Latifyan, S.
    Bartolini, R.
    Joo, V.
    Mederos, N.
    Bouchaab, H.
    Demicheli, R.
    Abdelhamid, K.
    Ferahta, N.
    Doms, J.
    Stalder, G.
    Noto, A.
    Mencarelli, L.
    Mosimann, V.
    Berthold, D.
    Stravodimou, A.
    Sartori, C.
    Shabafrouz, K.
    Thompson, J. A.
    Wang, Y.
    Peters, S.
    Pantaleo, G.
    Obeid, M.
    ANNALS OF ONCOLOGY, 2025, 36 (04) : 444 - 459
  • [46] CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity
    Li, Ji
    Piskol, Robert
    Ybarra, Ryan
    Chen, Ying-Jiun J.
    Li, Jason
    Slaga, Dionysos
    Hristopoulos, Maria
    Clark, Robyn
    Modrusan, Zora
    Totpal, Klara
    Junttila, Melissa R.
    Junttila, Teemu T.
    SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (508)
  • [47] Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
    Wu, Jingjing
    Fu, Jiaping
    Zhang, Mingzhi
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [48] Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
    Jingjing Wu
    Jiaping Fu
    Mingzhi Zhang
    Delong Liu
    Journal of Hematology & Oncology, 8
  • [49] Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy-Induced Cytokine Release Syndrome
    Minami, Soichiro
    Kawashima, Yosuke
    Munakata, Yasuhiko
    Matsuno, Masahiro
    Hara, Shuichiro
    Yamazaki, Yusuke
    Doman, Tsuyoshi
    Saito, Shin
    Odaka, Tetsuo
    Ogasawara, Takahiro
    Shimizu, Hisashi
    Sugisaka, Jun
    Aiba, Tomoiki
    Toi, Yukihiro
    Yamanda, Shinsuke
    Kimura, Yuichiro
    Sugawara, Shunichi
    CANCER REPORTS, 2024, 7 (07)
  • [50] Generation of a novel ROR1 x CD3 bispecific T-cell engager for better tumor killing and minimal cytokine release
    Wu, Danqing
    Gong, Shiyong
    Wu, Xuan
    Naren, Gaowa
    Dong, Liqin
    Lensky, Stephan
    Wu, Chengbin
    CANCER RESEARCH, 2024, 84 (07)
12345